An immune-enriched TME is characterized by high PD-L1 expression on the tumor cell surface, high number of effector immune cells (e.g., CD8+ T-cells, natural killer cells), and immunostimulatory cytokines and chemokines (i.e. interferons). Here, CD8A is linked to neoplasm.